{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T12:48:52Z","timestamp":1648990132001},"reference-count":16,"publisher":"Japanese Urological Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2018,4,20]]},"DOI":"10.5980\/jpnjurol.109.68","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T22:10:22Z","timestamp":1555625422000},"page":"68-73","source":"Crossref","is-referenced-by-count":0,"title":["THE USE OF BORTEZOMIB FOR THE TREATMENT OF CHRONIC ANTIBODY MEDIATED REJECTION AFTER KIDNEY TRANSPLANTATION"],"prefix":"10.5980","volume":"109","author":[{"given":"Masayuki","family":"Tasaki","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Nobushita","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Anraku","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Kuroki","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naofumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical and Dental Sciences, Niigata University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Loupy A, Hill GS and Jordan SC: The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat. Rev. Nephrol., 8, 348, 2012.","DOI":"10.1038\/nrneph.2012.81"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD and Chapman JR: The natural history of chronic allograft nephropathy. N. Engl. J. Med., 349, 2326, 2003.","DOI":"10.1056\/NEJMoa020009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Li C and Yang CW: The pathogenesis and treatment of chronic allograft nephropathy. Nat. Rev. Nephrol., 5, 513, 2009.","DOI":"10.1038\/nrneph.2009.113"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Billing H, Rieger S, Ovens J, Susal C, Melk A, Waldherr R, Opelz G and Tonshoff B: Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation, 86, 1214-1221, 2008.","DOI":"10.1097\/TP.0b013e3181880b35"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP and Gaspert A: Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation, 87, 1837-1841, 2009.","DOI":"10.1097\/TP.0b013e3181a6bac5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D and Suberbielle-Boissel C: Comparison of combination plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant, 9, 1099-1107, 2009.","DOI":"10.1111\/j.1600-6143.2009.02591.x"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A and Woodle ES: Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation, 86, 1754-1761, 2008.","DOI":"10.1097\/TP.0b013e318190af83"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI and Dave SD: Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation, 87, 1555-1561, 2009.","DOI":"10.1097\/TP.0b013e3181a4b91b"},{"key":"9","unstructured":"9) Macklin PS, Morris PJ and Knight SR: A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. Transplant Rev (Orlando) 2017. pii: S0955-470X (16) 30114-8."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ and Stegall MD: Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant, 9, 201-209, 2009.","DOI":"10.1111\/j.1600-6143.2008.02461.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA and Voll RE: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med, 14, 748-755, 2008.","DOI":"10.1038\/nm1763"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Philogene MC, Sikorski P, Montgomery RA, Leffell MS and Zachary AA: Differential effect of bortezomib on HLA class I and class II antibody. Transplantation, 98 (6), 660-665, 2014.","DOI":"10.1097\/TP.0000000000000132"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL and Rock KL: Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem, 272 (20), 13437-13445, 1997.","DOI":"10.1074\/jbc.272.20.13437"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hughes EA, Hammond C and Cresswell P: Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc Natl Acad Sci U S A, 94 (5), 1896-1901, 1997.","DOI":"10.1073\/pnas.94.5.1896"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Touzot M, Couvrat-Desvergnes G, Castagnet S, Cesbron A, Renaudin K, Cantarovich D and Giral M: Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. Transplantation, 99 (1), 63-68, 2015.","DOI":"10.1097\/TP.0000000000000285"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS and Huh KH: The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation. Yonsei Med J, 56 (6), 1638-1642, 2015.","DOI":"10.3349\/ymj.2015.56.6.1638"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/109\/2\/109_68\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T03:45:09Z","timestamp":1555731909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/109\/2\/109_68\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,20]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.109.68","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,20]]}}}